Login to Your Account



Cascade crusade: Apellis taking delivery of $47M in C3 'p.o.' box for trials

By Randy Osborne
Staff Writer

Friday, February 12, 2016

Apellis Pharmaceuticals Inc.'s $47.1 million in series D money will let the company reach "some inflection points in rare diseases and geographic atrophy [GA] in the next year or so," general counsel David Watson told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription